Optimizing Outcomes for Patients with DOAC-Related Bleeding: A Multidisciplinary Appraisal of Data-Driven Management Strategies Using Specific Reversal Agents

In this episode of CME-Pod, leading clinical experts - Drs. Truman Milling, Jr, Deborah Siegal, and Geoffrey Barnes - will provide learners with a circumscription of the clinical benefits and risks associated with DOAC usage, inclusive of patient-specific, disease-specific, and drug-specific risk factors, and will examine the unique pharmacologic mechanisms of established and emerging specific reversal therapeutics. A review of the evidentiary base will follow, encompassing completed, ongoing, and planned clinical trials for specific reversal agents, as well as recent readouts and pending regulatory updates that have the potential to meaningfully shift the calculus. The session will conclude with a case-based segment that tangibly highlights the imperative need for multidisciplinary collaboration and the importance of individualized, data-driven treatment selection.To access the webinar on Healio, complete the post-test and activity evaluation, and claim your CE credit, please follow this link: https://cme.healio.com/cardiology/20240112/optimizing-outcomes-for-patients-with-doac-related-bleeding